516 related articles for article (PubMed ID: 26933176)
1. PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma.
Field MG; Decatur CL; Kurtenbach S; Gezgin G; van der Velden PA; Jager MJ; Kozak KN; Harbour JW
Clin Cancer Res; 2016 Mar; 22(5):1234-42. PubMed ID: 26933176
[TBL] [Abstract][Full Text] [Related]
2. Relationship between clinical features, GEP class, and PRAME expression in uveal melanoma.
Schefler AC; Koca E; Bernicker EH; Correa ZM
Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1541-1545. PubMed ID: 31065847
[TBL] [Abstract][Full Text] [Related]
3. PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.
Gezgin G; Luk SJ; Cao J; Dogrusöz M; van der Steen DM; Hagedoorn RS; Krijgsman D; van der Velden PA; Field MG; Luyten GPM; Szuhai K; Harbour JW; Jordanova ES; Heemskerk MHM; Jager MJ
JAMA Ophthalmol; 2017 Jun; 135(6):541-549. PubMed ID: 28448663
[TBL] [Abstract][Full Text] [Related]
4. Uveal Melanomas with SF3B1 Mutations: A Distinct Subclass Associated with Late-Onset Metastases.
Yavuzyigitoglu S; Koopmans AE; Verdijk RM; Vaarwater J; Eussen B; van Bodegom A; Paridaens D; Kiliç E; de Klein A;
Ophthalmology; 2016 May; 123(5):1118-28. PubMed ID: 26923342
[TBL] [Abstract][Full Text] [Related]
5. Driver Mutations in Uveal Melanoma: Associations With Gene Expression Profile and Patient Outcomes.
Decatur CL; Ong E; Garg N; Anbunathan H; Bowcock AM; Field MG; Harbour JW
JAMA Ophthalmol; 2016 Jul; 134(7):728-33. PubMed ID: 27123562
[TBL] [Abstract][Full Text] [Related]
6. New concepts in the molecular understanding of uveal melanoma.
Reichstein D
Curr Opin Ophthalmol; 2017 May; 28(3):219-227. PubMed ID: 28257297
[TBL] [Abstract][Full Text] [Related]
7. Gene Expression Profiling and PRAME Status Versus Tumor-Node-Metastasis Staging for Prognostication in Uveal Melanoma.
Cai L; Paez-Escamilla M; Walter SD; Tarlan B; Decatur CL; Perez BM; Harbour JW
Am J Ophthalmol; 2018 Nov; 195():154-160. PubMed ID: 30092184
[TBL] [Abstract][Full Text] [Related]
8. Chromosome 3 status combined with BAP1 and EIF1AX mutation profiles are associated with metastasis in uveal melanoma.
Ewens KG; Kanetsky PA; Richards-Yutz J; Purrazzella J; Shields CL; Ganguly T; Ganguly A
Invest Ophthalmol Vis Sci; 2014 Jun; 55(8):5160-7. PubMed ID: 24970262
[TBL] [Abstract][Full Text] [Related]
9. Association of Uveal Melanoma Metastatic Rate With Stochastic Mutation Rate and Type of Mutation.
Szalai E; Jiang Y; van Poppelen NM; Jager MJ; de Klein A; Kilic E; Grossniklaus HE
JAMA Ophthalmol; 2018 Oct; 136(10):1115-1120. PubMed ID: 30073324
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in Class 1 and Class 2 uveal melanomas.
Field MG; Durante MA; Decatur CL; Tarlan B; Oelschlager KM; Stone JF; Kuznetsov J; Bowcock AM; Kurtenbach S; Harbour JW
Oncotarget; 2016 Sep; 7(37):59209-59219. PubMed ID: 27486988
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Germline versus Somatic BAP1 Mutations for Risk of Metastasis in Uveal Melanoma.
Ewens KG; Lalonde E; Richards-Yutz J; Shields CL; Ganguly A
BMC Cancer; 2018 Nov; 18(1):1172. PubMed ID: 30477459
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Value of BAP1 and Preferentially Expressed Antigen in Melanoma (PRAME) Immunohistochemistry in Uveal Melanomas.
Han LM; Lee KW; Uludag G; Seider MI; Afshar AR; Bloomer MM; Pekmezci M
Mod Pathol; 2023 Apr; 36(4):100081. PubMed ID: 36788079
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of chromosomal aberrations and GNAQ, GNA11 and BAP1 mutations in uveal melanoma.
Staby KM; Gravdal K; Mørk SJ; Heegaard S; Vintermyr OK; Krohn J
Acta Ophthalmol; 2018 Feb; 96(1):31-38. PubMed ID: 28444874
[TBL] [Abstract][Full Text] [Related]
14. Metastatic Disease in Polyploid Uveal Melanoma Patients Is Associated With BAP1 Mutations.
Yavuzyigitoglu S; Mensink HW; Smit KN; Vaarwater J; Verdijk RM; Beverloo B; Brüggenwirth HT; van Marion R; Dubbink HJ; Paridaens D; Naus NC; de Klein A; Kiliç E;
Invest Ophthalmol Vis Sci; 2016 Apr; 57(4):2232-9. PubMed ID: 27116551
[TBL] [Abstract][Full Text] [Related]
15. Genomic, prognostic, and cell-signaling advances in uveal melanoma.
Harbour JW
Am Soc Clin Oncol Educ Book; 2013; ():388-91. PubMed ID: 23714557
[TBL] [Abstract][Full Text] [Related]
16. Bioinformatics analysis of GNAQ, GNA11, BAP1, SF3B1,SRSF2, EIF1AX, PLCB4, and CYSLTR2 genes and their role in the pathogenesis of Uveal Melanoma.
Akin-Bali DF
Ophthalmic Genet; 2021 Dec; 42(6):732-743. PubMed ID: 34353217
[TBL] [Abstract][Full Text] [Related]
17. Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma.
Robertson AG; Shih J; Yau C; Gibb EA; Oba J; Mungall KL; Hess JM; Uzunangelov V; Walter V; Danilova L; Lichtenberg TM; Kucherlapati M; Kimes PK; Tang M; Penson A; Babur O; Akbani R; Bristow CA; Hoadley KA; Iype L; Chang MT; ; Cherniack AD; Benz C; Mills GB; Verhaak RGW; Griewank KG; Felau I; Zenklusen JC; Gershenwald JE; Schoenfield L; Lazar AJ; Abdel-Rahman MH; Roman-Roman S; Stern MH; Cebulla CM; Williams MD; Jager MJ; Coupland SE; Esmaeli B; Kandoth C; Woodman SE
Cancer Cell; 2017 Aug; 32(2):204-220.e15. PubMed ID: 28810145
[TBL] [Abstract][Full Text] [Related]
18. Multi-Modality Analysis Improves Survival Prediction in Enucleated Uveal Melanoma Patients.
Drabarek W; Yavuzyigitoglu S; Obulkasim A; van Riet J; Smit KN; van Poppelen NM; Vaarwater J; Brands T; Eussen B; Verdijk RM; Naus NC; Mensink HW; Paridaens D; Boersma E; van de Werken HJG; Kilic E; de Klein A;
Invest Ophthalmol Vis Sci; 2019 Aug; 60(10):3595-3605. PubMed ID: 31425584
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Implications of Tumor Diameter in Association With Gene Expression Profile for Uveal Melanoma.
Walter SD; Chao DL; Feuer W; Schiffman J; Char DH; Harbour JW
JAMA Ophthalmol; 2016 Jul; 134(7):734-40. PubMed ID: 27123792
[TBL] [Abstract][Full Text] [Related]
20. BAP1 Loss Is Associated with DNA Methylomic Repatterning in Highly Aggressive Class 2 Uveal Melanomas.
Field MG; Kuznetsov JN; Bussies PL; Cai LZ; Alawa KA; Decatur CL; Kurtenbach S; Harbour JW
Clin Cancer Res; 2019 Sep; 25(18):5663-5673. PubMed ID: 31285370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
